Brief: Biomarin To Acquire Inozyme Pharma
16/05/2025 12:38
May 16 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O: BIOMARIN STRENGTHENS ENZYME THERAPY BUSINESS WITH ACQUISITION OF INOZYME PHARMA INOZYME PHARMA INC - BIOMARIN TO BUY INOZYME FOR $270 MILLION INOZYME PHARMA INC - BIOMARIN REAFFIRMS 2025 FINANCIAL GUIDANCE Source text: ID:nPn7HZbjva Further company coverage: BMRN.O
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife